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Abstract
Background: There is a small but measurable increased risk of lymphoma in inflammatory bowel 
disease [IBD], with a suggestion that primary intestinal lymphoma [PIL] in IBD is associated with 
inflamed tissue and immunosuppressant use, mainly thiopurines.
Methods: This multicentre case series was supported by the European Crohn’s and Colitis 
Organisation [ECCO] and performed as part of the Collaborative Network of Exceptionally Rare 
case reports [CONFER] project. Clinical data were recorded in a standardized case report form.
Results: Fifteen patients with intestinal lymphoma from eight centres were included (12 males, 
11 patients with Crohn’s disease [CD], mean age 47.8 [±16.4 SD, range 26–76] years at lymphoma 
diagnosis). Lymphoma type was diffuse large B-cell lymphoma [DLBCL] in eight, Hodgkin’s disease 
in two, mucosa-associated lymphoid tissue [MALT] lymphoma in three, and single cases of 
immunoblastic lymphoma and indolent T-cell lymphoma. Lymphoma was located within the IBD-
affected area in ten patients. At lymphoma diagnosis, nine patients had a history of azathioprine 
or anti-tumour necrosis factor [TNF] use. Lymphoma was diagnosed at a mean time of 10.4 [±7.07, 
1–24] years after IBD diagnosis in 11 patients, prior to IBD in two and concurrently in two. Sustained 
remission over a median follow-up time of 6.5 [1.5–20] years was achieved in ten patients after 
treatment; five of them had started biological therapy [including anti-TNFs, vedolizumab and 
ustekinumab] for active CD subsequent to their PIL treatment.
Conclusion: In this small case series, two-thirds of patients developed lymphoma in the IBD-
affected area, and almost two-thirds had a history of thiopurine or anti-TNF use. Biologics were 
restarted without recurrence of lymphoma in half of the remitters.
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1.  Introduction
It has long been recognized that there is a slightly increased risk 
of malignancy in inflammatory bowel disease [IBD], which include 
Crohn’s disease [CD] and ulcerative colitis [UC], compared to the 
general population. The chronic inflammatory process can give rise 
to gastrointestinal carcinogenesis, with the risk of developing colo-
rectal adenocarcinoma estimated to be 1% annually.1 There is also 
an increased risk of lymphoproliferative disease [LD] particularly in 
IBD patients exposed to thiopurines either as monotherapy or com-
bined with anti-tumour necrosis factor [TNF] agents.2–4 A  similar 
risk in large population studies of IBD patients not exposed to 
immunosuppressants has not been shown.5 The relationship be-
tween immunosuppressants leading to LD is also recognized in the 
transplant literature, where chronic immunosuppression can lead 
to the development of post-transplant lymphoproliferative disease 
[PTLD].6,7
Primary intestinal lymphoma [PIL], also known as primary in-
testinal lymphoproliferative disease, accounts for only 1–4% of all 
gastrointestinal malignancies. There are three case series and a few 
additional case reports in the literature of PIL associated with IBD.8–
19 Shephard et al. reported on ten cases of lymphoma [seven in UC 
and three in CD] in the colon and rectum.8 Holubar et al. reported 
on 15 cases from the Mayo Clinic in the pre-biologic era (93% male, 
median age of IBD diagnosis 30 [interquartile range, IQR 22–51] 
years, median age of PIL diagnosis 47 [IQR 28–68] years, 66% 
CD). Location was colorectal in 60%, small bowel in 27%, and one 
case each in stomach, duodenum and ileal pouch.9 Most cases of 
lymphoma arose in inflamed tissues and affected those exposed to 
immunosuppression, whilst Epstein–Barr virus [EBV] was frequently 
implicated. In an observational sub-study from the CESAME cohort, 
the intestines were involved in a quarter of cases [gastric and duo-
denal cases were excluded]. Sokol et al. reported on 14 IBD patients 
identified with PIL, in nearly 20 000 patients with IBD in this co-
hort.10 This gives a significantly higher risk of PIL in IBD compared 
with the general population, although the absolute risk was low 
[crude incidence of 0.12/1000 patient years]. All 14 cases were non-
Hodgkin’s B-cell lymphoma, with 79% occurring in CD, 79% in 
males with a mean age of 55.1 [±5.6] years at lymphoma diagnosis 
and a median time from IBD diagnosis of 8.0 [IQR 3.0–15.8] years. 
The risk was highest in those exposed to thiopurines; 86% were lo-
cated within IBD lesions and 46% were found to be EBV-positive.10
We aimed to describe the clinical presentation, risk factors and 
outcome of a series of IBD patients with PIL.
2.  Case Report
This was a retrospective multicentre case series supported by the 
European Crohn’s and Colitis Organisation [ECCO], and performed 
as part of the ECCO Collaborative Network for Exceptionally Rare 
case reports [CONFER] project. A call to all ECCO members was 
made to report on cases of ‘Extranodal intestinal lymphoma in in-
flammatory bowel disease’. Clinical data were recorded in a stand-
ardized data collection form including: demographics, Montreal 
classification, previous medications, PIL-related location and type, 
time to diagnosis, treatments and outcome.
2.1.  Patients’ demographics
Our series included 15 IBD patients with PIL treated in eight dif-
ferent centres (12 males [80.0%], mean [±SD, range] age 40.2 [±21.0, 
13–76] years at IBD diagnosis and 46.4 [±17.0, 26–76] years at PIL 
diagnosis). Patients’ baseline characteristics are shown in Table 1. Six 
patients had other significant comorbidities including Parkinson’s 
disease, myasthenia gravis, cardiovascular disease, Addison’s disease, 
diabetes and autoimmune polyglandular syndrome type II. An IBD-
related surgery was performed in two patients prior to PIL diagnosis 
[ileocaecal resection in one, perianal drainage in one].
2.2.  Primary intestinal lymphoma diagnosis
The diagnosis of PIL occurred at a mean time of 10.4 [±7.1, 1–24] 
years after IBD diagnosis in 11 patients, prior to IBD in two and 
Table 1. Baseline characteristics [n = 15]
CD/UC 11/4
Male/female 12/3
Smoking history  
• Current/previous/never 3/1/11
Family history  
• IBD/PIL 0/0
Montreal classification  
• Colonic/ileocolonic/small bowel 3/4/4
• Inflammatory/stricturing/penetrating 7/1/3
•  Proctitis/left-sided/extensive 
colitis
2/1/1
IBD treatment prior to PIL diagnosis  
• Azathioprine 7 [mean dur-
ation 9 years]
• Anti-TNF 2 [one 8 months 
and one 3 years]
• 5ASA 1
• No IBD medications 5
PIL, primary intestinal lymphoma; IBD, inflammatory bowel disease; CD, 
Crohn’s disease; UC, ulcerative colitis; anti-TNF, anti-tumour necrosis factor; 
5ASA, 5-aminosalicylic acid.
Table 2. PIL characteristics
N=
Time of PIL diagnosis in relation to IBD diagnosis
• PIL diagnosed after IBD 11 [mean time 10.4 years]
• PIL diagnosed concurrently with IBD 3
• PIL diagnosed before IBD 1
Lymphoma type
• DLBCL 8 [7 CD, 1 UC]
• Hodgkin’s lymphoma 2 [both CD]
• MALT lymphoma 3 [2 CD, 1 UC]
• Indolent T-cell lymphoma 1 [UC]
• Immunoblastic lymphoma 1 [UC]
Lymphoma location
• Rectum 3
• Colon 4 [including 1 at  
anastomosis]
• Small bowel 4
• Stomach 1
• Multiple GI sites 3
Presentation
• Bowel obstruction 9
• Abdominal mass [non-obstructing] 2
• Others 4
PIL location in relation to IBD location
• In area affected by IBD 10
• In area distant to IBD 5
PIL, primary intestinal lymphoma; IBD, inflammatory bowel disease; CD, 
Crohn’s disease; UC, ulcerative colitis; DLBCL, diffuse large B-cell lymphoma, 
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Figure 1. Endoscopic and histological images of a Hodgkin’s lymphoma at the ileo-transverse colonic anastomosis. [A] Hodkin’s lymphoma. [B] Ulceration of 
mucous membranes due to lymphoma. [C] Lymphoma aggregate [magnification ×20]. [D] Ki-67 [magnification ×5]. [E] CD15-positive blasts. [F] CD30-positive 
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concurrently with IBD in two. The mean age of the four patients 
with a pre- or concurrent diagnosis was 52.5 [±17.8, 26–76] years, 
with no personal or family history of haematological disease. PIL 
characteristics for all 15 patients included in this series are shown 
in Table 2, whilst characteristics, treatment and outcome for each 
patient are given in Table 3. Diagnosis was made with the use of 
cross-sectional imaging and endoscopy, and histological confirm-
ation was obtained in all cases. Selective endoscopic and histological 
images are shown in Figure 1.
PIL was located within the IBD-affected area in ten patients [six in 
the large bowel, three in the small bowel, and one in both ileum and 
rectum concurrently, with four of these having active intestinal inflam-
mation at the time of diagnosis]. There was no extraintestinal or bone 
marrow involvement in any patient, except for the case of immunoblastic 
lymphoma who had non-contiguous extraintestinal spread.
IBD treatment was discontinued in the seven patients on 
azathioprine and the single patient on infliximab. Thirteen patients 
received PIL-related therapy, with seven receiving chemotherapy and 
surgery and six receiving only chemotherapy. The regimens are de-
tailed in Table 3. Remission was achieved in ten patients after treat-
ment with no signs of relapse at last follow-up. Three died from their 
PIL despite treatment: one with colonic CD and diffuse large B-cell 
lymphoma [DLBCL], one with UC proctitis and immunoblastic 
lymphoma with plasma cell differentiation, and one with UC proc-
titis and mucosa-associated lymphoid tissue [MALT] lymphoma 
throughout the large and small bowel. Two are being monitored 
without therapy: one with an indolent T-cell lymphoma and the 
other with a gastric MALT lymphoma. The latter was not associated 
with Helicobacter pylori, and no further signs of lymphoma were 
found after 2 years of endoscopic follow-up.
IBD-related treatment was resumed in 11/15 patients [Table 3]. 
One of these patients was treated with 5-aminosalicylic acid [5ASA] 
and oral steroids, later developing lymphoma recurrence and dying 
from this. No signs of PIL relapse were reported in the rest at last 
follow-up, at a median 6.5  years after PIL diagnosis [range 1.5–
20 years]. This included five patients [three with DLBCL in remission 
and two with Hodgkin’s lymphoma in remission] who have started 
biologics [infliximab in two cases, adalimumab in one, vedolizumab 
in one, and vedolizumab followed by ustekinumab in one], all for 
active luminal CD.
3.  Discussion
This is a retrospective, international study reporting on a series of 
PIL in IBD patients, and the course of both PIL and subsequent IBD 
therapy. This study was not designed to assess the prevalence of PIL 
in IBD. Our series has shown some similarities with the previous case 
series, but also some important differences.
Similar to the Mayo and CESAME cohort series,9,10 we also ob-
served that PIL mainly occurred in middle-aged men [80.0%], with 
an average age of 47.8 years at diagnosis. PIL was more frequently 
diagnosed in CD [11/15] than UC patients, and the most common 
histological type was B-cell lymphoma, including an immunoblastic 
lymphoma with plasma cell differentiation [9/15].
The diagnosis of PIL occurred at a mean of 10.4 [±7.1, 1–24] 
years after IBD diagnosis, which is less than the 17 years reported in 
the Mayo series,9 and more compatible with the 8 years reported in 
the CESAME series.10 However, two patients were diagnosed with 
PIL simultaneously with IBD, highlighting the possibility that both 
may be present at the same time. Diagnostic work-up includes a 
combination of clinical presentation of major abdominal symptoms 
not always attributed to IBD, cross-sectional imaging and endos-
copy [if accessible], with compatible histological features, the last 
being a prerequisite for diagnosis. In some cases, diagnosis is made 
only after surgical resection of an obstructing lesion and subsequent 
histological examination of the resection specimen. Bowel obstruc-
tion was the most common clinical presentation, whereas bloody 
diarrhoea has been previously reported as equally common in other 
series.9,10 Endoscopic features are not always pathognomonic.
The Mayo clinic and CESAME cohort series identified immuno-
suppressants and active intestinal inflammation as potential risk fac-
tors for the development of PIL.9,10 Sixty per cent of the cases in 
our series [9/15] may be related to these medications. Two-thirds 
developed PIL in the area affected by IBD inflammation, but that 
means a third of patients developed PIL in an area not involved in 
intestinal inflammation. Clinicians should therefore be mindful of 
this possibility. Two-thirds [10/15] achieved remission after receiving 
the appropriate PIL-related treatment.
A potential clinical dilemma is whether immunosuppressants 
can be safely restarted after lymphoma diagnosis. Our series shows 
IBD therapy was resumed in 11 patients, with relapse of PIL 
occurring in one case only that was probably unrelated to treat-
ment. This includes five patients who restarted biologics for active 
luminal CD, including anti-TNFs, vedolizumab and ustekinumab, 
and none of them reported recurrence of lymphoma at last 
follow-up.
In conclusion, this case series of PIL in IBD illustrates a strong 
male predilection and a wide histological type range, with the 
majority being DLBCL. It is notable that two-thirds of patients 
had a history of thiopurine or anti-TNF use, and two-thirds devel-
oped PIL in the luminal site affected by IBD. The majority of cases 
successfully recovered after appropriate treatment and, in half of 
them, IBD therapy was resumed uneventfully. However, these re-
sults are based on a small case series and should be interpreted 
with caution.
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